Clinical Trial: A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT06942442) titled 'A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma' on March 21.

Brief Summary: This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).

Study Start Date: Aug. 25, 2025

Study Type: INTERVENTIONAL

Condition: HLA-A*0201 Positive Cells Present Clear Cell Sarcoma (CCS)

Intervention: DRUG: Physician's Choice

Patients who are HLA-A*02:01-negative and ineligible to receive tebentafusp will be prospectively enrolled onto a separate study arm and treated with physicians' choice of treatment. They will also be ...